Two novel estrogen receptor b (ERb) mRNA isoforms that diverge in their 5 0 -untranslated regions, ERb mRNA (0K-1) and ERb mRNA (0N-1), have recently been identified. This indicates that transcription of the human ERb gene occurs from at least two different promoters, named promoter 0K and promoter 0N. The aim of this study was to investigate the expression of ERb isoforms in primary cultures of normal breast epithelial cells, a panel of breast cancer cell lines and in normal breast and breast cancer tissues; and to examine whether methylation of the two ERb promoters is involved in regulation of ERb gene expression. Using quantitative real-time PCR techniques, we found that ERb mRNA levels were significantly lower in breast cancer cell lines than in primary cultures of normal breast epithelial cells. Bisulfite genomic sequencing analysis revealed that two promoters of the ERb gene exhibit distinct methylation patterns. Promoter 0N was unmethylated in normal breast epithelial cells, but extensively methylated in breast cancer cell lines. In contrast, promoter 0K was unmethylated in both normal and malignant breast epithelial cells. We demonstrated a significant correlation between promoter 0N hypermethylation and loss of ERb mRNA expression in breast cancer cell lines. Treatment of breast cancer cells with demethylating agent effectively reactivated the expression of ERb mRNA. The observations from the cell lines were also reflected in primary breast cancer tumors. Thus, expression of ERb mRNA in breast tumors was found to be inversely associated with the degree of methylation of promoter 0N. Our results suggest that a decreased level of ERb mRNA may be associated with breast tumorigenesis, and that DNA methylation is an important mechanism for ERb gene silencing in breast cancer.
Two novel estrogen receptor b (ERb) mRNA isoforms that diverge in their 5 0 -untranslated regions, ERb mRNA (0K-1) and ERb mRNA (0N-1), have recently been identified. This indicates that transcription of the human ERb gene occurs from at least two different promoters, named promoter 0K and promoter 0N. The aim of this study was to investigate the expression of ERb isoforms in primary cultures of normal breast epithelial cells, a panel of breast cancer cell lines and in normal breast and breast cancer tissues; and to examine whether methylation of the two ERb promoters is involved in regulation of ERb gene expression. Using quantitative real-time PCR techniques, we found that ERb mRNA levels were significantly lower in breast cancer cell lines than in primary cultures of normal breast epithelial cells. Bisulfite genomic sequencing analysis revealed that two promoters of the ERb gene exhibit distinct methylation patterns. Promoter 0N was unmethylated in normal breast epithelial cells, but extensively methylated in breast cancer cell lines. In contrast, promoter 0K was unmethylated in both normal and malignant breast epithelial cells. We demonstrated a significant correlation between promoter 0N hypermethylation and loss of ERb mRNA expression in breast cancer cell lines. Treatment of breast cancer cells with demethylating agent effectively reactivated the expression of ERb mRNA. The observations from the cell lines were also reflected in primary breast cancer tumors. Thus, expression of ERb mRNA in breast tumors was found to be inversely associated with the degree of methylation of promoter 0N. Our results suggest that a decreased level of ERb mRNA may be associated with breast tumorigenesis, and that DNA methylation is an important mechanism for ERb gene silencing in breast cancer. Oncogene (2003 Oncogene ( ) 22, 7600-7606. doi:10.1038 Keywords: ERb; DNA methylation; mRNA isoform; breast cancer A body of evidence in humans and in animal models has suggested a role for estrogens in the growth of the mammary gland and in breast cancer progression (Gustafsson and Warner, 2000; Palmieri et al., 2002) . Most of the actions of estrogen are mediated through its binding to two estrogen receptor (ER) proteins, ERa and ERb that belong to a large family of transcription factors, the nuclear receptor family (Mangelsdorf et al., 1995) . However, the exact roles of ERa and ERb in breast cancer initiation and progression are still unclear, especially in the case of the recently discovered ERb (Kuiper et al., 1996) . Like many other genes, ERb is expressed as different mRNA isoforms (Palmieri et al., 2002) . Wild-type ERb (ERb1) encodes the full-length 530 amino-acid receptor protein, while ERb2 (ERbcx), which utilizes an alternative exon 8, encodes a variant receptor with a different C-terminus (Ogawa et al., 1998b) . More recently, additional complexity with regard to ERb isoforms has been introduced as ERb mRNAs which diverge in their 5 0 -untranslated regions have been identified (Hirata et al., 2001) . These are generated by alternative splicing of two upstream exons, exon 0K and exon 0N, to exon 1 (Figure 1 ). These results indicate that transcription of the human ERb gene occurs from at least two different promoters, named promoter 0K and promoter 0N.
Until now, knowledge of the expression of ERb isoforms in normal human breast epithelial cells has been very limited. Several groups have reported the expression of ERb isoforms in normal breast tissues and breast carcinoma Fuqua et al., 1999; Leygue et al., 1999; Iwao et al., 2000a, b; Palmieri et al., 2002; Tong et al., 2002) . Some data suggest that ERb1 mRNA is downregulated during breast tumorigenesis (Leygue et al., 1998 Iwao et al., 2000a) , but this does not appear to be the case in all grades of breast cancer (Palmieri et al., 2002) . Higher ERb2 expression as compared to ERb1 expression was observed in breast cancer cell lines Iwao et al., 2000a; Palmieri et al., 2002) .
DNA methylation occurs almost exclusively at cytosines located within CpG dinucleotides. However, clusters of CpG dinucleotides known as CpG islands, which are associated with the promoter region of many genes, are generally unmethylated. Methylation of CpG islands within promoter regions is one mechanism for gene inactivation during cancer development, as demonstrated for several tumor suppressor genes (Garinis et al., 2002) .
Recently, the promoter 0N of the ERb gene has been characterized (Li et al., 2000) . This region harbors a CpG island and may therefore be regulated by DNA methylation. We observed that the distal promoter 0K, which has not yet been well characterized, also includes a typical CpG island. In this study, we have investigated the expression of ERb isoforms as well as the methylation status of the two promoters involved in regulation of ERb gene expression in primary cultures of normal breast epithelial cells, breast cancer cell lines, and normal and malignant breast tissues. Detailed analysis of ERb mRNA expression and promoter methylation status was performed using quantitative real-time PCR and bisulfite genomic sequencing methods, respectively. We also investigated the effect of demethylation on ERb isoform expression by treating cells with 5-aza-2 0 -deoxycytidine, a DNA methyltransferase inhibitor.
Two novel ERb mRNA isoforms containing distinct 5 0 -untranslated regions, referred to as ERb mRNA (0K-1) and ERb mRNA (0N-1), have recently been identified. They are generated by alternative splicing of two upstream exons, exon 0K and exon 0N, to exon 1 (Figure 1 ). The presence of mRNA variants with different 5 0 -untranslated regions revealed the use of different promoters. We determined ERb mRNA (0K-1) and ERb mRNA (0N-1) expression levels in order to investigate the possibility of epigenetic modification of the two distinct promoters, termed promoter 0K and promoter 0N. Expression of ERb mRNA (0K-1) and ERb mRNA (0N-1) was studied by a quantitative realtime PCR assay in three primary cultures of normal breast epithelial cells and a panel of 17 breast cancer cell lines. As summarized in Figure 2 , all three cultures of normal breast epithelial cells expressed high levels of ERb mRNA (0N-1). In contrast, the majority of the tumor cell lines expressed undetectable or reduced levels of ERb mRNA (0N-1). Therefore, ERb mRNA (0N-1) expression is downregulated in breast cancer cell lines. Among the 17 breast cancer cell lines, the levels of ERb mRNA (0N-1) varied dramatically. The variation in ERb mRNA (0K-1) expression between normal breast epithelial cells and tumor cell lines was smaller. There was no correlation between the levels of mRNAs transcribed from promoters 0K and 0N, respectively.
We hypothesized that downregulation of the ERb gene in breast cancer was through promoter methylation. Comprehensive analysis of the percentage of CpG island methylation was performed by bisulfite genomic sequencing. DNA from the three normal breast epithelial cell cultures and 17 breast cancer cell lines was isolated and modified with bisulfite, which converts cytosine residues to uracil while methylcytosine remains unaltered. CpG-rich regions were defined as stretches of DNA that had both a >50% GC content and an observed-overexpected frequency of CpG dinucleotides of >0.6 (Gardiner-Garden and Frommer, 1987) . Analysis of the distal promoter 0K and exon 0K showed a 64.7% GC content and an observed-overexpected CpG frequency of 0.72, suggesting that promoter 0K is also a target of aberrant methylation. A 295-bp region of the CpG island of the promoter 0K, encompassing 14 CpG sites (Figure 1 ), was amplified by PCR from bisulfite-modified DNA. The methylation status for 13 CpG sites was clearly determined by direct sequencing. The results revealed that the CpG sites were unmethylated in all the three normal breast epithelial cells and 17 cell lines. One representative DNA-sequence is shown in Figure 3 (1).
The ERb gene promoter 0N has recently been cloned and characterized (Li et al., 2000) . This region is GCrich with a GC content of 65%. The amplified sequence (from À377 to À105 bp; Figure 1 ) used to assess the methylation status of promoter 0N contains altogether 27 CpG sites of which the methylation status for 23 CpG sites was clearly determined by direct sequencing ( Figure  3 (2)). No methylation in the promoter 0N CpG regions was found in the normal breast epithelial cells. By contrast, extensive methylation in this region was observed in most breast cancer cell lines. The average degree of methylation of these 23 CpG sites in DNA samples obtained from three normal breast epithelial cells and 17 breast cancer cell lines is shown in Figure 2 .
We further evaluated whether there is any relationship between ERb mRNA (0N-1) levels and the methylation status of promoter 0N. As shown in Figure 2 , all three normal breast epithelial cell cultures showing no methylation expressed abundant ERb mRNA (0N-1), whereas four cell lines (BT20, MDAMB453, HMT3522 and HBL100), in which the promoter is completely methylated, showed a loss of, or very low level of, ERb mRNA (0N-1) expression. Five cell lines (MDAMB231, MCF7, MDAMB468, ZR75-30 and BT549) showing low levels of promoter methylation (o50%) expressed relatively higher ERb mRNA (0N-1) levels. Correlation analysis confirmed that the methylation status of promoter 0N was significantly associated with the loss of ERb mRNA (0N-1) expression (r ¼ À0.8; P ¼ 0.001).
The ERb gene is subject to complex splicing (Lewandowski et al., 2002) . We next examined the expression of the most studied mRNA isoforms, ERb1 and ERb2, to relate their expression to methylation status. Using real-time PCR, the ERb1 and ERb2 mRNA levels ( Figure 2) were quantified in three normal 0 -untranslated region, locations of the CpG sites within amplified regions, and two mRNA isoforms (Hirata et al., 2001) . Translation start site is indicated by ATG. The A of the first codon ATG is assigned to nucleotide number þ 1. Each vertical bar represents a CpG site. The numbers above indicate sequence position as assigned by Hirata et al. (2001) ; 'intron': bases 148 431 to 148 567, GenBank accession number AL122035; numbers between the exons indicate the intron length ERb methylation and expression in breast cancer C Zhao et al breast epithelial cell cultures and 17 breast cancer cell lines. The results showed that both ERb1 and ERb2 mRNA levels were significantly lower in tumor cell lines than in normal breast epithelial cells (P ¼ 0.001 and 0.001, respectively). ERb2 mRNA expression was more pronounced than that of ERb1, and the difference between the mean levels was statistically significant (P ¼ 0.04). Both ERb1 and ERb2 mRNA levels were found to be inversely associated with the mean methylation degree (Figure 2 ) of the promoter 0N (r ¼ À0.8, P ¼ 0.001; r ¼ À0.8, P ¼ 0.001, respectively).
To further investigate whether methylation of the ERb promoter was responsible for the loss of ERb expression, we treated BT20, HBL100, HMT3522 and MDAMB453 cell lines with 5-aza-2 0 -deoxycytidine, a DNA methyltransferase inhibitor. 5-aza-2 0 -deoxycytidine reactivated ERb mRNA (0N-1) as well as ERb1 and ERb2 expression as detected by real-time PCR (Figure 4 ). In contrast, methylation inhibition was unable to reactivate ERb mRNA (0K-1) expression.
To assess whether the correlation between ERb promoter methylation and ERb mRNA expression described above for breast cancer cell lines can be extended to primary breast tumors, we examined methylation of promoters 0N and 0K and expression of ERb mRNA (0K-1), ERb mRNA (0N-1), ERb1 and ERb2 in two normal breast tissues and 33 primary breast tumor samples. Using bisulfite modification and direct sequencing of the ERb promoters 0K and 0N region as described above, the results indicated that the promoter 0K was unmethylated in both normal breast tissues and breast tumors, while promoter 0N was methylated in most breast tumors but unmethylated in normal breast tissues. The average degree of promoter Figure 2 ERb mRNA (0K-1), ERb mRNA (0N-1), ERb1 and ERb2 levels determined by real-time PCR and the corresponding degree of promoter 0N methylation in three normal breast epithelial cell primary cultures (N1, N2 and N3) and 17 breast cancer cell lines. Three human breast samples were obtained with the approval of the local ethics committee and consent from women who underwent breast reduction mammoplasty at Charing Cross Hospital, London and St Georges Hospital, London, UK. Normal breast epithelial cells were prepared from reduction mammoplasty as described previously (Gomm et al., 1995) . Total cellular RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed as described (Bieche et al., 2001) . Expression of ERb mRNA isoforms was quantitatively analysed by real-time PCR. Primer sequences were 0 -TCCTGATGCTCCTGTCCCACGTCA-3 0 for both ERb1 and ERb2. For normalization of the amount of sample RNA added to each reaction, transcripts of b-glucuronidase were quantified as the endogenous reference (Iwao et al., 2000b) . PCR reactions were run on an ABI Prism 7700 Sequence Detection System (Applied Biosystems). The amplification mixtures contained 3 ml of cDNA template in a 25 ml reaction volume containing 1 Â TaqMan Universal PCR Master Mix (Applied Biosystems), 50 nM probe and 100 nM of each primer. PCR was carried out after incubation at 501C for 2 min, denaturing at 951C for 10 min, 45 cycles of 951C for 15 s, and 601C for 1 min. The amount of target gene mRNA and reference mRNA expression was determined using standard curves generated by serial dilutions of cDNA from the BT549 breast cancer cell line. The normalized expression level of target gene mRNAs was determined by dividing the amount of target mRNA by the amount of b-glucuronidase mRNA ERb methylation and expression in breast cancer C Zhao et al 0N methylation in DNA samples obtained from two normal breast and 33 breast tumors is shown in Table 1 . We next analysed expression levels of ERb mRNA (0K-1), ERb mRNA (0N-1), ERb1 and ERb2 in breast tissues using real-time PCR (Table 1) . Owing to the limited availability of normal human breast tissue, only two normal breast tissues were included in this study and they had high levels of ERb mRNA (0N-1), ERb1 and ERb2. Consistent with the data from the cell lines, expression of ERb mRNA (0N-1), ERb1 and ERb2 in breast tumors was found to be inversely associated with the methylation degree of promoter 0N (r ¼ À0.4, P ¼ 0.04; r ¼ À0.5, P ¼ 0.003; r ¼ À0.4, P ¼ 0.04, respectively). The expression of ERb mRNA (0K-1) was lower than that of other isoforms. There was no significant correlation between the methylation status of promoter 0N and clinicopathological factors with respect to histological grade, tumor size and lymph node status. No correlations were found between the ERb mRNA expression levels and these clinicopathological factors (data not shown).
Even though the role of ERb in human breast is not fully understood, emerging data show clearly that ERb is expressed in breast cancer. Several studies have found that there is lower ERb mRNA expression in breast carcinomas in comparison to normal breast tissue (Leygue et al., 1998 Iwao et al., 2000a) . In this study, we demonstrate that ERb mRNA expression is decreased in human breast cancer cells as compared to normal breast epithelial cells. So far, no significant genetic alterations within the ERb gene in human breast cancer have been reported, suggesting that epigenetic modification of ERb gene via hypermethylation may represent an important alternative mechanism for inactivation of this gene in breast cancer.
In humans, tissue-specific expression of the ERa gene has been shown to be regulated by multiple promoters (Flouriot et al., 1998) . Recently, isoforms of the ERb Genomic DNA was modified with sodium bisulfite as described earlier (Herman et al., 1996) . This treatment resulted in the conversion of unmethylated cytosine to thymine, whereas the methylated cytosine remained unchanged. A volume of 2 ml of bisulfite-modified DNA was subjected to PCR amplification (annealing temperature 601C). Primers were designed to amplify both bisulfite-modified methylated and unmethylated DNA but not unmodified DNA. The primer sequences for amplifying the ERb promoter 0K region were as follows: upper 5 0 -GTTGGGGTTATTTCGGGGTTGTT-3 0 , and lower 5 0 -CCTCCAACAAAACAAACACATTCA-3 0 . The 295-bp amplified fragment covered sequence from a region 137 bp upstream of the exon 0K (bases 148 431-148 567 GenBank accession number AL122035) and extending 158 bp into exon 0K (À289 to À132 with respect to translation initiation site) (see Figure 1) . The primer sequences for amplifying the ERb promoter 0N region were as follows: upper 5 0 -TTCGTTAGGAGGTAGTTGTAAG-3 0 , and lower 5 0 -CACCGACCTTACCTTCTCTAAAATA-3 0 (Nojima et al., 2001) . The 273-bp amplified fragment corresponds to the ERb exon 0N sequences À377 to À105 with respect to translation initiation site (see Figure 1) . The degree of methylation at each CpG site was expressed as the peak height of the methylated cytosine relative to the peak height of total cytosine (methylated plus unmethylated). The average degree of methylation for individual samples was expressed as the mean of the percentage of each CpG site examined ERb methylation and expression in breast cancer C Zhao et al mRNA which diverge in their 5 0 -untranslated regions were identified (Hirata et al., 2001) . They were generated by alternative splicing of two upstream exons, exon 0K and exon 0N, to exon 1, indicating that transcription of the human ERb gene occurs from at least two different promoters. We therefore analysed the methylation status of these two promoters and corresponding mRNA expression in normal breast epithelial cells, a panel of breast cancer cell lines and normal breast and breast cancer tissues. Our results show that ERb mRNA (0N-1) expression was more pronounced than that of ERb mRNA (0K-1) expression. Prior to this investigation, only one study has analysed the distribution of these two isoforms and detected expression from both promoters in several human tissues, such as liver, ejaculated spermatozoa, uterine endometrium and myometrium (Hirata et al., 2001) . Since these two transcripts differ only in the noncoding region at the 5 0 -end, their significance remains unknown.
We found that ERb mRNA (0N-1) levels in breast cancer cell lines were significantly lower than in primary cultures of normal breast epithelial cells, and that the methylation status of promoter 0N region correlated significantly with the level of ERb mRNA (0N-1) expression. Promoter 0K was found to be unmethylated in all samples examined. In accordance with these observations, treatment of four breast cancer cell lines with the demethylating agent 5-aza-2 0 -deoxycytidine, reactivated ERb mRNA (0N-1) expression but was unable to reactivate ERb mRNA (0K-1) expression. These results indicated that hypermethylation of promoter 0N plays a role in silencing ERb gene expression. We also observed that the two promoter regions of the ERb gene exhibit distinct methylation patterns in breast cancer. These data are in agreement with another study which showed that different ERa promoters exhibited heterogeneous methylation patterns in prostate cancer (Sasaki et al., (Omoto et al., 2002) . Findings in the present study revealed that ERb1 and ERb2 mRNA levels were decreased in breast cancer cell lines as compared to normal breast epithelial cells in primary cultures, suggesting that ERb may play a role in breast tumorigenesis. We further examined whether hypermethylation of promoter 0N is involved in the regulation of ERb1 and ERb2 expression. We found that both ERb1 and ERb2 mRNA levels correlated inversely with the methylation status of promoter 0N in breast cells. Furthermore, ERb1 and ERb2 expression was restored by treatment with the demethylating agent 5-aza-2 0 -deoxycytidine. These results indicate that promoter methylation was responsible for silencing ERb1 and ERb2 expression in human breast cancer cells. This concurs with one recent report which showed that the reduction of ERb protein in prostate cancer is associated with methylation of the ERb promoter (Nojima et al., 2001) . There is little data regarding the relative contributions of promoters 0N and 0K to the final ERb1 and ERb2 transcripts. However, it has been shown that the ERb1 cDNA sequence contains exon 0N (Moore et al., 1998) , while ERb2 cDNA sequences have been reported, which contain either exon 0N (GenBank accession number AF051428) or exon 0K (Ogawa et al., 1998b) . It should be noted that ERb1 and ERb2 mRNAs were detected in some cell lines and breast tumor samples exhibiting loss of or less ERb mRNA transcribed from either promoter 0N or promoter 0K and that high levels of ERb mRNA (0N-1) were observed in some tumor samples exhibiting low level of ERb1 and ERb2 mRNAs. These results suggest the presence of an additional promoter(s) and that promoter 0N may regulate the expression of other ERb isoform(s) such as ERb3 transcript. Indeed, full-length ERb cDNA sequence containing neither exon 0N nor exon 0K (Ogawa et al., 1998a) and ERb3 cDNA sequence containing exon 0N (GenBank accession number AF060555) have been reported. Further studies on cloning and characterization of promoter 0K or other putative promoters should help to elucidate the entire regulatory mechanism of the human ERb gene expression.
In agreement with the data from the cell lines, our results also showed that downregulation of ERb expression in primary breast cancers is associated with promoter hypermethylation. In contrast to breast cancer cell lines, less extensive methylation and higher mRNA expression were observed in breast cancer tissues. This may be a consequence of contamination by normal cells and heterogeneity of cell types with different ERb expression levels within the tumor samples. This is consistent with our observations that two normal breast tissues had high levels of ERb mRNA isoforms and absence of promoter 0N methylation. Higher ERb mRNA expression in normal breast in comparison to breast cancers has been reported by several authors (Leygue et al., 1998 Iwao et al., 2000a) . Additionally, ERb expression in breast has been found in a range of cells such as in epithelial cells, stromal cells, myoepithelial cells and lymphocytes (Skliris et al., 2001) . Bieche et al. (2001) reported that ERb mRNA expression showed wide variations (nearly three orders of magnitude) in a series of 131 breast tumors, consistent with the data obtained in the present study. Our observation that ERb expression levels did not correlate with clinicopathological factors such as histological grade, tumor size and lymph node status is consistent with other studies (Iwao et al., 2000a; Bieche et al., 2001) , in which a large number of breast cancer patients was included.
There are several possibilities to explain methylationmediated suppression of gene expression. Firstly, methylation can directly interfere with the DNA binding of certain transcription factors (Tate and Bird, 1993) . Sequence analysis of the 5 0 -flanking region of ERb promoter 0N has shown the presence of several consensus transcriptional factor binding sites and cisregulatory elements (Li et al., 2000) . Secondly, some methyl-CpG binding proteins (e.g. MeCP2) are able to change DNA conformation and thus affect the binding of various transcriptional regulators Kokura et al., 2001) .
In this study, we have shown that ERb mRNA expression is decreased in human breast cancer cells as compared to normal breast epithelial cells, and that DNA methylation is an important mechanism for silencing ERb gene expression in breast cancer. Since DNA methylation is potentially reversible, these findings point to a new potential target in treatment of breast cancer. Indeed, DNA methylation inhibitors are being widely studied as promising therapeutic agents (Karpf and Jones, 2002) .
